Senesco Technologies, Inc. Corporate Overview OTC QB: SNTI BIO San Diego June, 2014 1 Certain statements included in this press release are forward - looking statements within the meaning of the Private Securities Litiga

Senesco Technologies, Inc. Corporate Overview OTC QB: SNTI BIO San Diego June, 2014 1

Certain statements included in this press release are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's ability to integrate the Fabrus science and operations; the Company's ability to continue as a going concern; the Company's ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company's gene and antibody technology; the approval of the Company's patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products; the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company's common stock on an over - the - counter securities market, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward - looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward - looking statements to reflect subsequent events or circumstances. 2 Safe Harbor Statement

Senesco - Fabrus Update Fabrus acquisition closed May 16, 2014 Administrative and financial integration largely complete Synergies: - targeted delivery of nanoparticles - Advanced biologics drug candidates and platforms Detailed strategy for combined company to be announced early calendar Q3 3

Senesco is A clinical stage biologic therapeutics company with next generation antibody and gene regulation product candidates and platforms Backed by world renowned investors and advisors - Pfizer - Opko Health - Phillip Frost - Chairman of TEVA, CEO of OPKO - Harlan Waksal - Founder of Imclone - Richard Lerner - Past president Scripps - Christopher Forbes - VP Forbes Media Using underlying proprietary enabling technologies to discover new product candidates for an internal pipeline or for out - licensing 4

Harlan Waksal , M.D . (chair) Founder, Imclone Systems Phillip Frost, M.D. Chairman TEVA, CEO OPKO Christopher Forbes Vice President, Forbes Media, LLC Vaughn Smider , M.D., Ph.D. Acting CEO, Senesco John Braca Former partner SRone ( Glaxo Smith - Kline) David Rector Principal David Stephen Group Steven Rubin COO, OPKO Board of Directors 5

The Senesco Opportunity Monoclonal antibodies - >$50B annual sales with 30+ FDA approved molecules in multiple therapeutic areas. - A proven drug class with a straightforward development path. - Senesco has a proprietary technology enabling discovery of first and best in class antibodies against certain large target classes Nanoparticle gene regulation - Gene and siRNA therapies are an emerging paradigm in disease treatment - Senesco has a proprietary position in eIF5a regulatory pathways, as well as unique nanocage delivery systems 6

Pipeline SNS01 - T - Nanoparticle for B - cell cancers - siRNA /Gene therapy targeting eIF5a - Induces apoptosis - Phase Ib / IIa trial expected to finish 2H 2014 - Multiple Myeloma, Diffuse Large Cell B - cell Lymphoma, Mantle Cell Lymphoma FB001 - The world's first therapeutic antibody against an ion channel - Based on novel cow antibody scaffold - Targets Kv1.3 on T - cells - Autoimmune/Inflammation indications - Unique mechanism of action - completely shuts off key inflammatory cytokines ( TNF a , IL - 17, etc.) without broad immunosuppression . - Phase I expected 2015/16 FB002 - Anti - Renal Cell Carcinoma - Unique antibody targeting angiogenesis pathways important in anti - VEGF resistance - Potential applications in other cancers - Phase I expected 2016 7

Core Technologies Monoclonal Antibody Discovery - Fully human antibodies (FB002) - Humanized cow antibody scaffold (FB001) - Addressed libraries for discovery against multipass membrane targets on cells Broad technology platform targeting eIF5a - Critical cell survival switch (SNS01 - T) Chimerasome nanocage delivery system 8

These two proteins act as a biological switch to promote cell death or survival CANCER Lysine F5A protein Cell Death amino acid Hypusine eIF5A Survival amino acid eIF5A Lysine and hypusine modifications control cell death and growth 9 SNS01 - T modulates eIF5A, Which Regulates Cell Growth and Death SNS01 - T

SNS01 - T Study Status Cohorts 1 - 3 completed The most frequent AEs are infusion reactions and thrombocytopenia 2/4 patients in cohort 3 have stable disease after 6 weeks of therapy Cohort 4 - Dose escalation to 0.375 mg/kg (6 patients). 3 evaluable patients have completed cohort 4. Results of cohort 4 expected 2H 2014 10

Antibody Discovery Technology: Finding Antibodies Directly on the Cell Surface Current antibody targets - "easy" soluble proteins or large extracellular domains. $50B market Next generation targets - complex targets, e.g. multipass transmembrane receptors, >$50 B market Senesco technology uses unique scaffolds (cow antibody) and identifies antibody lead candidates directly on the cell surface 11

Cow Antibodies: a Novel Scaffold for Targeting Membrane Proteins Wang et.al. (2013) Cell 153 : 1379 - 1393 (featured on the cover) Human Cow Ultralong binding region 12

Engineered Cow Antibodies Targeting Ion Channels Kv1.3 Ion channel IL - 17 (A450, sem ) Inhibition of human effector - memory T - cells Including IL - 17, TNF, and others at pM IC 50 s Autoimmune/Inflammation 13

Future Plans Advance two antibodies to the clinic in 18 - 24 months Establish robust pipeline of antibody and nanoparticle biologics Further develop SNS01 - T Drug development partnerships In - license new product candidates and synergistic technologies Goal: become the preeminent advanced biologics company with best and first in class product candidates and technologies 14

World - class science, management team, and board Dr. Harlan Waksal , Founder of ImClone Dr. Phillip Frost, Chairman of Teva Near - term clinical trial results from Phase 1b/2a study Combination with Fabrus provides "product engine" in next generation antibodies cow antibody coupled with discovery technology enables antibodies against difficult transmembrane targets Multi - billion opportunity in several therapeutic areas 15 Summary

Corporate Information Senesco Technologies, Inc. 721 Route 202/206, Suite 130 Bridgewater, NJ 08807 Phone: 908 - 864 - 4444 www.senesco.com OTCQB: SNTI 16